Metabolic parameters predict survival and toxicity in chimeric antigen receptor T‐cell therapy‐treated relapsed/refractory large B‐cell lymphoma

Author:

Ababneh Hazim S.1ORCID,Ng Andrea K.2,Abramson Jeremy S.3,Soumerai Jacob D.3,Takvorian Ronald W.3,Frigault Matthew J.3,Patel Chirayu G.1

Affiliation:

1. Department of Radiation Oncology Massachusetts General Hospital Harvard Medical School Boston Massachusetts USA

2. Department of Radiation Oncology Brigham and Women's Hospital, Harvard Medical School Boston Massachusetts USA

3. Division of Hematology and Oncology Massachusetts General Hospital Harvard Medical School Boston Massachusetts USA

Abstract

AbstractCD19‐targeted chimeric antigen receptor (CAR) T‐cell therapy has revolutionized treatment for patients with relapsed/refractory large B‐cell lymphoma (LBCL). However, data available concerning the impact of the prognostic value of quantitative 18F‐fluorodeoxyglucose positron emission tomography‐computed tomography (FDG PET/CT) parameters on the CAR T‐related outcomes and toxicities are limited. Therefore, we aimed to evaluate the predictive value of pre‐ and post‐CAR T metabolic parameters on survival and toxicities following CAR T‐cell therapy. Fifty‐nine patients with PET/CT scans done pre‐and post‐CAR T infusion were retrospectively identified and analyzed in a single institution database of LBCL patients treated with commercial CD19‐targeted CAR T‐cell therapy. The median follow‐up was 10.7 months [interquartile range (IQR): 2.6–25.5 months]. The overall response (complete response‐CR and partial response) and CR rates post‐CAR T were 76% (n = 45) and 53% (n = 31), respectively. On univariate analysis, low pre‐CAR T total lesion glycolysis (TLG) and metabolic tumor volume (MTV) predicted improved overall response post‐CAR T (OR = 4.7, p = 0.01, OR = 9.5, p = 0.03, respectively) and CR post‐CAR T (OR = 12.4, p = 0.0004, OR = 10.9, p = 0.0001, respectively). High TLG pre‐CAR T was correlated with cytokine release syndrome (CRS, OR = 3.25, p = 0.04). High MTV pre‐CAR T was correlated with developing immune effector cell neurotoxicity syndrome (ICANS) events (OR = 4.3, p = 0.01), and high SUV pre‐CAR T was associated with grade 3–4 neurological events (OR = 12, p = 0.01). High MTV/TLG/SUVmax post‐CAR T were significantly associated with inferior Overall survival (OS). On multivariate analysis, high TLG pre‐CAR T (HR = 2.4, p = 0.03), age ≥60 (HR = 2.7, p = 0.03), and bulky disease (≥5 cm) at the time of apheresis (HR = 2.5, p = 0.02) were identified to be independent prognostic factors for inferior PFS. High MTV post‐CAR T was identified as the most prognostic factor associated with inferior OS.

Publisher

Wiley

Subject

Cancer Research,Oncology,Hematology,General Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3